ArticleClinical case reports2026
Concomitant Hypertriglyceridemia-Induced Pancreatitis and Diabetic Ketoacidosis in the Setting of Olanzapine Use: A Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute pancreatitis is a rare but serious complication associated with antipsychotic medications, such as olanzapine. Hypertriglyceridemia-induced pancreatitis is an uncommon, potentially life-threatening etiology, and severe metabolic abnormalities may be further complicated by diabetic ketoacidosis. The concomitant occurrence of these conditions is rare and requires increased clinical awareness. We present the case of a 43-year-old male with bipolar disorder who had been on olanzapine therapy for 2.5 months. He presented with back pain and was diagnosed with hypertriglyceridemia-induced pancreatitis and diabetic ketoacidosis. Laboratory evaluation revealed severe metabolic disturbances, including triglyceride levels exceeding 5000 mg/dL. Olanzapine was promptly discontinued, and the patient received appropriate supportive care, resulting in full clinical recovery. This case underscores the potential metabolic side effects of olanzapine, emphasizing the importance of regular monitoring of blood glucose and lipid levels, especially in patients at higher risk for metabolic disturbances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.